Skip to Main content Skip to Navigation
Journal articles

Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins

Abstract : Adverse immune responses severely hamper the success of biopharmaceutical therapies. Possible clinical consequences include anaphylaxis, reduced drug half‐life and neutralization of the therapeutic protein as well as the endogenous human homologue. Controlling potential triggers of the immune system helps to minimize the immunogenicity of biopharmaceuticals, a crucial consideration in biopharmaceutical manufacturing. This review summarizes the latest advancements that have been made towards insight into the impact of structural characteristics on the immunogenicity of therapeutic proteins. Examples are given to illustrate the role of critical quality attributes, such as protein conformation, glycosylation, chemical modifications and aggregation, in immunogenicity. During the development of biopharmaceutical products, it is important to not just assess the risk for immunogenicity in clinical trials, but to ensure product quality throughout drug design, cell‐line selection, upstream and downstream processing, all the way to to the final product.
Complete list of metadatas

https://hal-normandie-univ.archives-ouvertes.fr/hal-01844668
Contributor : Arnaud Lehner <>
Submitted on : Thursday, July 19, 2018 - 3:42:12 PM
Last modification on : Friday, April 5, 2019 - 3:24:07 PM

Links full text

Identifiers

Citation

Miranda van Beers, Muriel Bardor. Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins. Biotechnology Journal, Wiley-VCH Verlag, 2012, 7 (12), pp.1473 - 1484. ⟨10.1002/biot.201200065⟩. ⟨hal-01844668⟩

Share

Metrics

Record views

36